Calyx IRT Reaches Milestone in Supporting 500 Global Regulatory Approvals Industry-proven randomization and trial supply management (RTSM) solution ensures reliability of drug supply and patient safety. News provided by Share this article Share this article NOTTINGHAM, United Kingdom, April 21, 2021 /PRNewswire/ -- Calyx, the eClinical and regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced its Interactive Response Technology (IRT) solution has reached a significant milestone. Global regulators have approved 500 medical treatments which included the use of Calyx IRT for randomization and trial supply management (RTSM) during clinical development. Gavin Nichols, CEO of Calyx is honored that so many global clinical researchers rely on Calyx IRT to remove RTSM risks, which became even more critical when sponsors and CROs turned to Calyx to come up with novel solutions for delivering study medication directly to patients in order to continue their important clinical development programs during COVID-19 stay-at-home mandates